RNA-Based Therapies for Lipoprotein(a) Reduction: Antisense Oligonucleotides, Small Interfering RNAs, and Emerging Platforms. (PubMed, Curr Atheroscler Rep) - Oct 15, 2026 - "This includes pelacarsen, an antisense oligonucleotide (ASO), and olpasiran, zerlasiran, and lepodisiran, which are N-acetylgalactosamine (GalNAc)-conjugated small interfering RNAs (siRNAs)...An oral small molecule, muvalaplin, achieved comparable reductions in phase 2 testing...The pharmacology of Lp(a) suppression is now well characterized across three distinct therapeutic modalities. Whether the magnitude of biochemical reduction observed translates into a meaningful and safe reduction in cardiovascular events across different populations remains undetermined and will be addressed by the ongoing outcomes trials."
First-in-human • Journal • Review • Atherosclerosis • Cardiovascular
|
|
Vera A Bittner; Vibhu Parcha
|